Monday, July 2, 2012
• Medivir AB of Stockholm, Sweden said that in July it will be initiating a Phase II combination study with TMC435 and daclatasvir (Bristol-Myers Squibb, BMS-790052).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.